ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 675,62
-0,26%
Dow Jones
39 375,87
0,17%
DAX
18 475,45
0,12%
Brent Oil
86,775
0,00%
Bitcoin
56 769,95
0,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cellectis SA (CLLS)

  7. Cellectis SA (CLLS) Actualités

CLLS

Cellectis (CLLS)

Cellectis SA
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CLLS
DateHeureSourceTitreSymboleSociété
28/06/202422h30GlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024NASDAQ:CLLSCellectis SA
20/06/202422h30GlobeNewswire Inc.Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingNASDAQ:CLLSCellectis SA
12/06/202422h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
12/06/202422h30GlobeNewswire Inc.Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsNASDAQ:CLLSCellectis SA
04/06/202422h30GlobeNewswire Inc.Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaNASDAQ:CLLSCellectis SA
29/05/202422h30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024NASDAQ:CLLSCellectis SA
28/05/202422h30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024NASDAQ:CLLSCellectis SA
27/05/202422h30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024NASDAQ:CLLSCellectis SA
06/05/202408h00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:CLLSCellectis SA
02/05/202422h30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerNASDAQ:CLLSCellectis SA
29/04/202422h46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:CLLSCellectis SA
22/04/202422h30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsNASDAQ:CLLSCellectis SA
10/04/202422h30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsNASDAQ:CLLSCellectis SA
08/04/202422h30GlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingNASDAQ:CLLSCellectis SA
16/01/202422h30GlobeNewswire Inc.Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)NASDAQ:CLLSCellectis SA
22/12/202322h30GlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023NASDAQ:CLLSCellectis SA
17/11/202322h30GlobeNewswire Inc.Cellectis’ Shareholders Meeting to be Held on December 22, 2023NASDAQ:CLLSCellectis SA
15/11/202308h30GlobeNewswire Inc.Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNASDAQ:CLLSCellectis SA
06/11/202322h30GlobeNewswire Inc.Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023NASDAQ:CLLSCellectis SA
02/11/202321h30GlobeNewswire Inc.Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNASDAQ:CLLSCellectis SA
01/11/202321h30GlobeNewswire Inc.Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023NASDAQ:CLLSCellectis SA
01/11/202320h15AllPennyStocks.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNASDAQ:CLLSCellectis SA
01/11/202312h52Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:CLLSCellectis SA
01/11/202309h17Dow Jones NewsAstraZeneca to Invest $245 Million in Deal With CellectisNASDAQ:CLLSCellectis SA
01/11/202308h00GlobeNewswire Inc.Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZenecaNASDAQ:CLLSCellectis SA
31/10/202322h10Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:CLLSCellectis SA
31/10/202321h30GlobeNewswire Inc.Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:CLLSCellectis SA
12/10/202322h30GlobeNewswire Inc.Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)NASDAQ:CLLSCellectis SA
27/09/202322h30GlobeNewswire Inc.Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:CLLSCellectis SA
05/09/202322h32Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:CLLSCellectis SA
 Showing the most relevant articles for your search:NASDAQ:CLLS

Dernières Valeurs Consultées

BIT
1JNJ
Johnson And Johnson
BIT
UII894
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés